Tata Chemicals Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹15,377 Cr
- ROE
- 1.27%
- Price to sales
- 1.03
- Debt to equity
- 0.38
- 52W high / low
- ₹912 / ₹577
- Sales growth (5Y)
- 7.41%
- EBITDA margin
- 11.20%
- Net profit margin
- 3.10%
- Promoter holding
- 37.98%
- Sales (last year)
- ₹15,120 Cr
Incorporated in 1939, Tata Chemicals Ltd manufactures and exports basic chemistry and specialty products [1]
Guidance scorecard · Q1 FY27 call
What Tata Chemicals Ltd's management guided
and where it ranks in Chemicals & Petrochemicals
Chemicals & Petrochemicals
RevenueQ1 FY27 call
10–20%- Overall, volume growth is expected to be modest in challenging segments with strategic capital allocation towards non-cyclical, higher-value products ensuring sustainable revenue growth.
MarginsQ1 FY27 call
FlatSee what Tata Chemicals Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- FY27 capex planned to be around INR 1,200 crores, aligned with depreciation; aim to stay below this level.
- Liquidation of INR 300 crores investments (stock and land) planned to support financials.
- Non-core land monetization expected in the second half of FY27, post Q2.
- Salt plant in India (82.5 KTPA) expected operational by end of 2026, supplying market by Q1 FY28.
- South India salt plant (210 KTPA) and 50 KTPA silica plant to become operational in 2028.
- Capex focus shifting towards Living Essentials (food, feed, pharma) over Industrial Essentials, aiming to de-commoditize portfolio and reduce cyclicality.
2 more points from Tata Chemicals Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY27 call
See what Tata Chemicals Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
Ask what Tata Chemicals Ltd said on the order book →
Full Q1 FY27 analysisRanges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Chemicals & Petrochemicals companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 0–2% | ₹263 Cr | 3.4 | |
| 2 | 40%+ | Flat | ₹4,375 Cr | 83.7 | |
| 3 | 40%+ | Flat | ₹3,259 Cr | 4.0 | |
| 4 | 40%+ | Flat | ₹145 Cr | 15.9 | |
| 5 | 20–40% | Up 2%+ | ₹1.81L Cr | 90.9 | |
| 6 | 20–40% | Up 2%+ | ₹48,366 Cr | 78.3 |
Sign up free to see every company in the sector ranking and track Tata Chemicals Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Chemicals & Petrochemicals rankingTata Chemicals Ltd announcements
All announcements →- Acquisition / mergerNotableTata Chemicals completes acquisition of North American soda ash customer contracts
Financials of Tata Chemicals Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Tata Chemicals Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 4,407 | 4,218 | 3,998 | 3,730 | 3,475 | 3,789 | 3,999 | 3,590 | 3,509 | 3,719 | 3,877 | 3,550 | 3,438 |
| Expenses + | 3,442 | 3,175 | 3,191 | 3,188 | 3,032 | 3,215 | 3,381 | 3,156 | 3,182 | 3,070 | 3,340 | 3,205 | 3,164 |
| Operating Profit | 965 | 1,043 | 807 | 542 | 443 | 574 | 618 | 434 | 327 | 649 | 537 | 345 | 274 |
| OPM % | 22% | 25% | 20% | 15% | 13% | 15% | 15% | 12% | 9% | 17% | 14% | 10% | 8% |
| Other Income + | 86 | 67 | 187 | 98 | -861 | 116 | 152 | -10 | 29 | 138 | 128 | 21 | -1,760 |
| Interest | 133 | 123 | 145 | 132 | 130 | 133 | 145 | 148 | 137 | 147 | 144 | 146 | 153 |
| Depreciation | 234 | 229 | 234 | 246 | 271 | 273 | 277 | 280 | 293 | 280 | 285 | 293 | 343 |
| Profit before tax | 684 | 758 | 615 | 262 | -819 | 284 | 348 | -4 | -74 | 360 | 236 | -73 | -1,982 |
| Tax % | -1% | 23% | 20% | 26% | 3% | 33% | 23% | 425% | -34% | 12% | 35% | -5% | 7% |
| Net Profit + | 692 | 587 | 495 | 194 | -841 | 190 | 267 | -21 | -49 | 316 | 154 | -69 | -2,116 |
| EPS in Rs | 27.83 | 20.88 | 16.80 | 6.20 | -33.36 | 5.89 | 7.61 | -2.08 | -2.20 | 9.89 | 3.02 | -3.65 | -83.67 |
Financials of Tata Chemicals Ltd
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 17,204 | 14,873 | 10,346 | 10,270 | 10,337 | 10,357 | 10,200 | 12,622 | 16,789 | 15,421 | 14,887 | 14,584 |
| Expenses + | 15,305 | 12,777 | 8,249 | 6,926 | 8,538 | 8,411 | 8,693 | 10,317 | 12,969 | 12,574 | 12,934 | 12,779 |
| Operating Profit | 1,900 | 2,096 | 2,097 | 3,344 | 1,799 | 1,945 | 1,506 | 2,305 | 3,820 | 2,847 | 1,953 | 1,805 |
| OPM % | 11% | 14% | 20% | 33% | 17% | 19% | 15% | 18% | 23% | 18% | 13% | 12% |
| Other Income + | 183 | 210 | 293 | 262 | 785 | 6,480 | 254 | 486 | 218 | -521 | 287 | -1,473 |
| Interest | 461 | 525 | 297 | 326 | 354 | 342 | 367 | 303 | 406 | 530 | 563 | 590 |
| Depreciation | 463 | 526 | 512 | 518 | 568 | 666 | 759 | 806 | 892 | 980 | 1,123 | 1,201 |
| Profit before tax | 1,159 | 1,255 | 1,580 | 2,763 | 1,661 | 7,416 | 634 | 1,682 | 2,740 | 816 | 554 | -1,459 |
| Tax % | 30% | 20% | 22% | 2% | 17% | 3% | 31% | 16% | 11% | 47% | 30% | 18% |
| Net Profit + | 802 | 1,006 | 1,234 | 2,702 | 1,387 | 7,228 | 436 | 1,405 | 2,434 | 435 | 387 | -1,715 |
| EPS in Rs | 23.41 | 30.24 | 38.98 | 95.49 | 45.37 | 274.97 | 10.06 | 49.37 | 90.93 | 10.52 | 9.22 | -74.41 |
| Dividend Payout % | 53% | 33% | 28% | 23% | 28% | 4% | 99% | 25% | 19% | 143% | 119% | -13% |
Financials of Tata Chemicals Ltd
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 |
| Reserves | 5,297 | 6,600 | 7,653 | 10,847 | 12,086 | 12,643 | 14,035 | 17,998 | 19,466 | 21,986 | 21,339 | 20,951 |
| Borrowings + | 8,379 | 9,090 | 7,072 | 6,108 | 6,130 | 7,702 | 6,933 | 7,024 | 6,296 | 5,563 | 7,072 | 8,001 |
| Other Liabilities + | 6,872 | 8,402 | 8,607 | 8,648 | 8,398 | 7,073 | 7,115 | 8,566 | 8,923 | 8,907 | 9,084 | 9,824 |
| Total Liabilities | 20,802 | 24,346 | 23,587 | 25,858 | 26,869 | 27,673 | 28,337 | 33,843 | 34,940 | 36,711 | 37,750 | 39,031 |
| Fixed Assets + | 11,359 | 13,431 | 12,644 | 12,787 | 13,551 | 15,356 | 15,261 | 16,044 | 17,092 | 17,861 | 19,600 | 20,626 |
| CWIP | 189 | 350 | 333 | 409 | 774 | 835 | 1,094 | 1,668 | 2,410 | 2,217 | 1,913 | 1,014 |
| Investments | 443 | 2,188 | 2,787 | 2,840 | 5,615 | 4,285 | 5,816 | 7,683 | 7,448 | 9,739 | 9,144 | 9,886 |
| Other Assets + | 8,811 | 8,377 | 7,822 | 9,822 | 6,929 | 7,198 | 6,167 | 8,448 | 7,990 | 6,894 | 7,093 | 7,505 |
| Total Assets | 20,802 | 24,346 | 23,587 | 25,858 | 26,869 | 27,673 | 28,337 | 33,843 | 34,940 | 36,711 | 37,750 | 39,031 |
Financials of Tata Chemicals Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 1,274 | 2,332 | 3,531 | 1,870 | 1,581 | 1,780 | 2,037 | 1,645 | 2,971 | 3,016 | 1,761 | 1,269 |
| Cash from Investing Activity + | -663 | -463 | -985 | 2,714 | -1,927 | -2,285 | -1,147 | -817 | -1,149 | -605 | -1,667 | -809 |
| Cash from Financing Activity + | -1,087 | -1,802 | -2,341 | -2,089 | -1,712 | -129 | -1,456 | -755 | -2,076 | -2,494 | 29 | -670 |
| Net Cash Flow | -477 | 68 | 205 | 2,494 | -2,058 | -634 | -565 | 73 | -254 | -83 | 123 | -210 |
| Free Cash Flow | 709 | 1,645 | 2,888 | 1,140 | 502 | 611 | 804 | 380 | 1,427 | 1,193 | -191 | 129 |
| CFO/OP | 86% | 129% | 190% | 71% | 115% | 99% | 142% | 83% | 88% | 120% | 102% | 67% |
Financials of Tata Chemicals Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 73 | 88 | 74 | 46 | 51 | 56 | 50 | 56 | 57 | 45 | 47 | 52 |
| Inventory Days | 137 | 119 | 244 | 304 | 315 | 347 | 257 | 318 | 282 | 341 | 324 | 353 |
| Days Payable | 138 | 99 | 232 | 307 | 269 | 302 | 256 | 338 | 289 | 320 | 318 | 293 |
| Cash Conversion Cycle | 72 | 107 | 86 | 43 | 97 | 100 | 51 | 35 | 50 | 66 | 53 | 113 |
| Working Capital Days | -4 | 31 | -4 | 27 | -2 | -102 | -28 | -29 | 29 | -22 | -21 | 1 |
| ROCE % | 11% | 11% | 10% | 16% | 9% | 36% | 4% | 8% | 12% | 8% | 4% | 4% |
Guidance history
How Tata Chemicals Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 10–20% | Flat | Planned | — | — |
| Q4 FY26 call → | 10–20% | Flat | Planned | — | — |
| Q3 FY26 call → | 10–20% | Flat | Planned | — | — |
| Q2 FY26 call → | 10–20% | Flat | Planned | Planned | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
10 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | −33.9% | 18% |
| Last 6 months | −25.4% | 12% |
| Last 3 months | −10.0% | 40% |
The price is 54.1% below its all-time high of ₹1,315.25 (7 Mar 2024). Stocks more than 20% below their peak have their score halved, so 20 became 10.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Tata Chemicals Ltd: 0.4 × 18 + 0.4 × 12 + 0.2 × 40 = 20, halved to 10 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Tata Chemicals Ltd's management said in earlier quarters
- Q3 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Chemicals & Petrochemicals this season
- Deepak Nitrite Ltd (Q2 FY27)
Q2 FY27 total revenue: ₹3,091 crore, up 61% YoY (Page 1, 4, 5, 6, 10, 11) . Key investor presentation takeaways from Deepak Nitrite Ltd's Q2 FY27 investor prese
- Privi Speciality Chemicals Ltd (Q2 FY27)
19,239.47 lakhs (approximately 33.9% growth). Key results statement takeaways from Privi Speciality Chemicals Ltd's Q2 FY27 results statement — and how it ranks
- NOCIL Ltd (Q2 FY27)
427 crores . Key investor presentation takeaways from NOCIL Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
- Neochem Bio Solutions Ltd (Q2 FY27)
Revenue from Operations for H1 FY27: ₹68.9 crores, up 50% YoY (from ₹45.8 crores in H1 FY26) [Page 22] . Key investor presentation takeaways from Neochem Bio So
